Biorez

Biorez is a technology company.

Closed

Website LinkedIn

Updated: Feb 17, 2026 ·

Recent News & Mentions

Sep 1, 2020FundingBiorez - Seed Mar 1, 2018FundingBiorez - Series C Jan 1, 2014FundingBiorez - Venture Round

Financial History

Biorez has raised $11.0M across 3 funding rounds. Most recently, it raised $4.0M Seed in September 2020.

Total Raised

$11.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
Sep 1, 2020	$4.0M Seed	5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Nextech Invest, OrbiMed, RA Capital
Mar 1, 2018	$2.0M Series C	5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Nextech Invest, OrbiMed, RA Capital
Jan 1, 2014	$5.0M Venture Round	5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Nextech Invest, OrbiMed, RA Capital

Financial History

Biorez has raised $11.0M across 3 funding rounds.

Total Raised

$11.0M

Valuation

N/A

Deep Dive

High-Level Overview

Biorez is a medical technology company specializing in orthopedics, developing the BioBrace scaffold, a bioinductive implant that reinforces tendon and ligament repairs while promoting soft tissue regeneration.[1][2][3] It serves surgeons and healthcare providers in specialties like orthopedics, addressing the challenge of weak soft tissue healing post-surgery by enabling cellular infiltration, vascular ingrowth, and gradual load-sharing as the implant resorbs.[1][3] Founded in 2016 in New Haven, Connecticut, Biorez raised $35.79M before being acquired by CONMED Corporation in August 2022 for a valuation between $85M and $250M, integrating its technology into CONMED's portfolio of surgical devices.[1][2]

Now operating as a CONMED company, Biorez continues to advance BioBrace, which is FDA-cleared in multiple sizes for minimally invasive procedures, demonstrating strong growth momentum through acquisition and commercialization in the soft tissue repair market.[1][2]

Origin Story

Biorez, formerly known as Soft Tissue Regeneration, was founded in 2016 in New Haven, Connecticut, by Kevin Rocco, who serves as President, CEO, and Founder.[1][2] The company emerged from a focus on innovating soft tissue regeneration in orthopedics, pioneering the BioBrace implant to overcome limitations in traditional repairs where tissues often fail to heal robustly.[1][3]

Early traction built around BioBrace's unique biocomposite design—a porous collagen sponge combined with bioresorbable polymer microfilaments—leading to FDA clearance and partnerships like with XVIVO for technology validation.[3] A pivotal moment came in August 2022 with its acquisition by CONMED, marking validation of its technology and enabling scaled distribution through CONMED's global surgical network.[1][2]

Core Differentiators

Biorez stands out in the medtech space through BioBrace's engineered features:

Biocomposite structure: Combines a highly porous collagen sponge for rapid cellular and vascular ingrowth with strong, bioresorbable polymer microfilaments for mechanical reinforcement, enabling load-sharing during healing.[1][3]
Regenerative mechanism: Open architecture facilitates fibroblast integration and gradual resorption, restoring native tissue without permanent implants, unlike synthetic alternatives.[3][4]
FDA-cleared versatility: Available in multiple sizes for tendon/ligament repairs in orthopedics and other surgeries, with proven stability for surgical sites.[1][2]
Acquisition-backed scale: Post-2022 CONMED integration provides manufacturing, distribution, and R&D resources, accelerating adoption among surgeons.[1]

Role in the Broader Tech Landscape

Biorez rides the wave of regenerative medicine and bioinductive implants, capitalizing on rising demand for solutions that enhance soft tissue outcomes in orthopedics amid an aging population and sports injury surge.[1][3] Timing aligns with advances in biomaterials, where bioresorbable scaffolds outperform autografts or synthetics by reducing re-tear rates and complications.[3][4]

Market forces like FDA's support for innovative devices and CONMED's dominance in minimally invasive surgery favor Biorez, influencing the ecosystem by setting a standard for hybrid collagen-polymer tech that could expand to general surgery or gynecology.[1][2] Its acquisition underscores investor confidence in orthobiologics, pushing competitors toward similar regenerative approaches.

Quick Take & Future Outlook

Biorez's BioBrace positions it for expansion within CONMED, potentially into new indications like rotator cuff repairs or ACL reinforcements, driven by clinical data on resorption and tissue restoration.[1][3] Trends in personalized orthopedics and biologics will shape its path, with AI-optimized scaffolds or combo therapies on the horizon.

As CONMED evolves its portfolio, Biorez could amplify influence in global medtech, redefining soft tissue repair from reinforcement to true regeneration—echoing its founding promise to advance healing beyond conventional limits.[2][4]

Sources

Frequently Asked Questions

How much funding has Biorez raised?

Biorez has raised $11.0M in total across 3 funding rounds.

Who are Biorez's investors?

Biorez's investors include 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Nextech Invest, OrbiMed, RA Capital.